(Total Views: 590)
Posted On: 01/27/2021 6:21:44 PM
Post# of 653
$RLFTF (copy) y5h--00 Big Rock Partners Acquisition Corp. FORM S-4
Released: January 27, 2021
Page: 173
https://fintel.io/doc/sec-big-rock-partners-a...27-18654-7
Our first VIP-derived product - ZYESAMI (RLF-100), the NeuroRx COVID-19 Drug - was awarded Fast Track designation by the FDA in June 2020 and admitted to the Coronavirus Treatment Acceleration Program. NeuroRx is currently conducting Phase 2b/3 clinical trials, with read out data expected by January 28, 2021.
With news from Gilles della Corte as well. We should see data very very soon.
Released: January 27, 2021
Page: 173
https://fintel.io/doc/sec-big-rock-partners-a...27-18654-7
Our first VIP-derived product - ZYESAMI (RLF-100), the NeuroRx COVID-19 Drug - was awarded Fast Track designation by the FDA in June 2020 and admitted to the Coronavirus Treatment Acceleration Program. NeuroRx is currently conducting Phase 2b/3 clinical trials, with read out data expected by January 28, 2021.
With news from Gilles della Corte as well. We should see data very very soon.
(1)
(0)
$MJ
Scroll down for more posts ▼
